Trial Profile

Phase I Study of Escalating Doses of XL888 With Vemurafenib Plus Cobimetinib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 25 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cobimetinib (Primary) ; Vemurafenib (Primary) ; XL 888 (Primary)
Indications Malignant melanoma
Focus Adverse reactions

Most Recent Events

22 Apr 2025 Planned End Date changed from 1 Mar 2025 to 1 Nov 2025.
15 Jan 2025 Planned End Date changed from 1 Dec 2024 to 1 Mar 2025.
20 Nov 2024 Planned End Date changed from 1 Oct 2024 to 1 Dec 2024.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com